Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
4 Results for "
VEGFR/PARP-IN-1
" in MedChemExpress (MCE) Product Catalog:
Products (4)
4 Results for "VEGFR/PARP-IN-1" in MCE Product Catalog:
Cat. No.: HY-155965
CAS No.: 3010256-54-6
VEGFR/PARP-IN-1 (Compound 14b) is a VEGFR/PARP dual inhibitor (IC50s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC50: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent .
Cat. No.: HY-W002016
CAS No.: 253-52-1
Target:
Research Areas:
Cardiovascular Disease Infection Metabolic Disease Inflammation/Immunology Cancer
Phthalazine is a chemical scaffold. Phthalazine derivatives act as VEGFR-2 inhibitors, PARP-1 inhibitors, and anticancer agents. The complex of phthalazine with silver exhibits broad-spectrum antibacterial and antifungal activities against Staphylococcus aureus, Enterococcus faecalis, Escherichia coli, Pseudomonas aeruginosa PAO1, and Candida albicans. Phthalazine derivatives possess potent vasodilatory activity. Phthalazine can be used in research related to colon adenocarcinoma, breast cancer, hypertension, diabetes, and microbial infections .
Cat. No.: HY-182005
EGFR/VEGFR2-IN-12 is a dual EGFR/VEGFR2 inhibitor, with an IC50 value of 64 nM against human EGFR and an IC50 value of 74 nM against human VEGFR2. EGFR/VEGFR2-IN-12 inhibits the phosphorylation of EGFR and VEGFR2, induces cell cycle arrest at the G1/S phase, activates apoptotic pathways, promotes PARP-1 cleavage, exhibits low micromolar antiproliferative activity, and shows much higher selectivity for cancer cells than normal cells. EGFR/VEGFR2-IN-12 is applicable for cancer-related research .
Cat. No.: HY-189264
Target:
Research Areas:
Anticancer agent-362 is a chimeric pyrrolidinedione-pyrrolidine-phthalazine-triazole (PPPT) heterocyclic derivative with antitumor activity. Anticancer agent-362 exhibits antiproliferative activity against breast adenocarcinoma and osteosarcoma cancer cell lines, with low toxicity to normal fibroblasts. Anticancer agent-362 is predicted to be a multi-target ligand that binds to the active sites of VEGFR-2, PARP-1, and others. Anticancer agent-362 can be used in research related to breast adenocarcinoma and osteosarcoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
